Dr Iain Dukes
Venture Partner at OrbiMed Advisors
Dr. Dukes is a Venture Partner at OrbiMed Advisors. He is also Chairman of Iovance Biotherapeutics (NASQ: IOVA) and serves on the Board of Directors of Themis Biosciences (acquired by Merck & Co), Ikena Oncology, KaNDy Therapeutics (previously as Chairman, acquired by Bayer AG), ReViral Limited, ENYO Pharma and Feldan Therapeutics. He co-founded and is CEO and Chairman of Theseus Pharmaceuticals and CEO of Viriom Inc. He co-founded and is President of Kartos Therapeutics and Telios Pharma. He is also Executive Chairman of Angiex and Chairman of the Loch family of oncology companies, of which six have been formed to date.
He previously served as SVP and Head of BD for Merck Research Laboratories and prior to that held R & D and BD leadership roles at Amgen and GSK.
He holds an M.A. and D.Phil, from the University of Oxford, an MSc. in Cardiovascular Studies from the University of Leeds, and a B.Sc. in Pharmacology from the University of Bath.